{"id":69,"date":"2019-02-20T16:12:05","date_gmt":"2019-02-20T16:12:05","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-news\/?p=69"},"modified":"2019-04-16T19:38:44","modified_gmt":"2019-04-16T19:38:44","slug":"dmf-drug-master-files","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-news\/2019\/02\/20\/dmf-drug-master-files\/","title":{"rendered":"DMF \u2013 DRUG MASTER FILES"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/www.fdahelp.us\/drug-master-files.html\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\">Drug Master File (DMF)<\/a> is a document submitted by a drug manufacturer to US FDA which is used to provide confidential detailed information about facilities, procedures, or things used in the manufacturing, processing, packaging, and storing of one or more human drugs. A DMF is submitted when more companies work in partnership to manufacture a drug product, which allows the company to protect is its intellectual property rights from its partner while complying with regulatory constraints as well for disclosing of processing procedures.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMF\u2019s are submitted to support regulatory regulations and prove\nthe quality, safety and effectiveness of a product for getting Investigational\nNew Drug Application (IND), New Drug Application (NDA), Abbreviated New Drug\nApplication(ANDA), another DMF and Export Application. However, DMF submission\nis NOT a substitute for an IND, NDA, ANDA or Export Application. As per FDA\nregulation, DMF submission is not required by law, it is solely depends to\nsubmitters discretion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As per FDA, there are five types of DMF\u2019s<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Type I&nbsp; :\nManufacturing Site, Facilities, Operating Procedures, and Personnel (no longer\napplicable)<\/li><li>Type II&nbsp; :\nDrug Substance, Drug Substance Intermediate, and Material Used in Their\nPreparation, or Drug Product<\/li><li>Type III :&nbsp;\nPackaging Material<\/li><li>Type IV&nbsp; :\nExcipient, Colorant, Flavor, Essence, or Material Used in Their Preparation<\/li><li>Type V :&nbsp;\nFDA Accepted Reference Information<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">All DMF submissions must be in the English language which\nshould contain transmittal letter, administrative information about the\nsubmission and must include specific information about the DMF type. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">All foreign DMF holders are required to appoint an <a href=\"https:\/\/www.fdahelp.us\/fda_registration\/us-fda-agents-requirements.html\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\">U.S agent<\/a>, however domestic DMF holders do not need a representative to submit it.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMF holders should submit an annual report on the same date\nof their original submission.&nbsp; Annual\nreport should contain all the information including name and address of DMF\nholder, corporate headquarters, Manufacturing\/ processing facility, contact for\nFDA communication, agents (if any),statement of commitment and signed statement\nby the DMF holder assuring that the DMF is current. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Starting from May 5, 2018 onwards, new DMFs other that Type\nIII, as well as all documents submitted to existing DMFs excluding Type III are\nrequired to submit DMF using Electronic Common Technical Document (eCTD).&nbsp; DMFs that are not submitted through eCTD\nafter May 5, 2018 will be rejected, however for Type III DMFs the requirement\nwill be effective from May 5, 2020 onwards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\" href=\"http:\/\/www.fdahelp.us\" target=\"_blank\">Liberty Management Group Ltd<\/a>, a leading FDA consulting group in the United States, provides assistance DMF eCTD submissions, US agent service, DMF closure and reactivation request submission to FDA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sudha S<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Regulatory Consultant<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mail: office@libertymanagement.us<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.fdahelp.us\">http:\/\/www.fdahelp.us<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Drug Master File (DMF) is a document submitted by a drug manufacturer to US FDA which is used to provide confidential detailed information about facilities, procedures, or things used in the manufacturing, processing, packaging, and storing of one or more human drugs. A DMF is submitted when more companies work in partnership to manufacture &hellip; <a href=\"https:\/\/www.libertymanagement.us\/fda-news\/2019\/02\/20\/dmf-drug-master-files\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DMF \u2013 DRUG MASTER FILES&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[11,12],"class_list":["post-69","post","type-post","status-publish","format-standard","hentry","category-fda-registration-drug","tag-fda-dmf-submission","tag-fda-us-agent-service"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/69","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=69"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/69\/revisions"}],"predecessor-version":[{"id":70,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/69\/revisions\/70"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=69"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=69"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=69"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}